2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
24
Urinary Bladder Neoplasms
5
Neoplasms
2
Urothelial Bladder Cancer
1
Urologic Neoplasms
1
Urinary Bladder Diseases
1
Stomach Neoplasms
1
Recurrence
1
Prostate cancer, familial
1
Parotid Neoplasms
1
Non-Muscle Invasive Bladder Neoplasms
1
Lung Neoplasms
1
Genetic Predisposition to Disease
1
Driving Under the Influence
1
Disease Progression
1
Disease
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Gemcitabine
9
pembrolizumab
7
Cisplatin
5
enfortumab vedotin
4
atezolizumab
4
Trastuzumab
4
Mitomycin
4
Carboplatin
4
Sunitinib
3
Pemetrexed
3
dodecyl maltoside
2
cabozantinib
2
Water
2
Sugammadex
2
Standard of Care
2
Saline Solution
2
Paclitaxel
2
Nivolumab
2
Neostigmine
2
Docetaxel
2
Cetuximab
2
Bevacizumab
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
vinflunine
1
valrubicin
1
tucatinib
1
tislelizumab
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Multiparametric Magnetic Resonance Imaging
×
Clear all
NCT04442724
2025-08-14
FMBRT
Cedars-Sinai Medical Center
Phase NA
Recruiting
60 enrolled